SMi Group are proud to announce the 9th Annual Orphan Drugs and Rare Diseases Conference, taking place on the 15th and 16th October 2019 in London, UK.
The orphan drug market is continuously growing and is expected to reach $176 billion by 2020, with a CGR of just for orphan drugs – this is twice the growth rate of the overall prescription drug market ( CGR from 2014-2020). By 2020, orphan drugs are set to account for 19% of global prescription sales.
This is due to the arising interest from pharmaceutical companies for underlying benefits, such as the potential discovery of mechanisms for more common diseases, and also the involvement of many smaller biotechnology start-up companies who are primarily focused on rare diseases.
The 2019 agenda features various key presentations by leading solution providers, biotechnology companies, clinical researchers, regulatory professionals and charity leaders discussing possible ways to accelerate orphan drug development and access to rare disease patients, including the introduction of recent technologies and products to help aid the access of orphan drugs.
BENEFITS OF ATTENDING
PLUS AN INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOP
Thursday 17th October 2019
A deep dive into strategies for accelerating patient access of orphan drugs
Workshop Leader: Workshop Leaders: Solange Corriol-Rohou, Senior Director Regulatory Affairs & Policy Europe, AstraZeneca
Cecile Ollivier, Chief Operating Officer, Aparito
WHO SHOULD ATTEND?
CEOs, CSOs, Vice Presidents, Directors, Heads, Principals working in:
For more details and to register or this event, visit the website at
15 Oct 2019 @ 08:30 am
16 Oct 2019 @ 05:00 pm
Duration: 1 days, 8 hours
Holiday Inn Kensington Forum, London UK